Research Units | Job Offer | Job Search | Personnel support areas


 

HOHLFELD Reinhard

Tel.: +49-89-7095-4436

Fax: +49-89-7095-7435

e-mail: hohlfeld@neuro.mpg.de

 

Address

Institut für Klinische Neuroimmunologie

Klinikum Grosshadern

Marchioninistr. 15

D-81377 München

Germany

Research themes

Research at the INIM focuses on the pathogenesis and treatment of multiple sclerosis, myasthenia gravis, myositis, and paraneoplastic neuroimmunological disorders. About 25 scientists from various countries and with varied backgrounds - biologists, biochemists, and physicians - cooperate in the laboratories located on the campus of University Hospital LMU-Großhadern and Max-Planck-Institute for Neurobiology in an effort to learn more about the pathogenesis und treatment of autoimmune diseases of the nervous system and skeletal muscle.

Key words

Methods

Composition of the research group

For further details see the Webpage of our Institute:
www.med.uni-muenchen.de/inim/home/home1e.htm

Recent publications

  1. STADELMANN C., KERSCHENSTEINER M., MISGELD T., BRÜCK W., HOHLFELD R., LASSMANN H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain, 125: 75-85, 2002.

  2. ZIEMSSEN T., NEUHAUS O., HOHLFELD R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug safety, 24: 979-990.

  3. WIENDL H., MALOTKA J., HOLZWARTH B., WELTZIEN H.-U., WEKERLE H., HOHLFELD R., DORNMAIR K. An autoreactive TCR derived from a polymyositis lesion. Journal of Immunology, 169: 515-521, 2002.

  4. ZIEMSSEN T., KÜMPFEL T., KLINKERT W.E.F., NEUHAUS O., HOHLFELD R. Glatiramer actate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain, 125: 2381-2391, 2002.

  5. FARINA C., WAGENPFEIL S., HOHLFELD R. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis: A pilot study. Journal of Neurology, 249: 1587-1592.

  6. *PANITCH H., GOODIN D.S., FRANCIS G., CHANG P., COYLE P.K., O´CONNOR P., MONAGHAN E., LI D., WEINSHENKER B., AND THE EVIDENCE STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI RESEARCH GROUP. Randomized, comparative study of interferon ß-1a treatment regimes in MS: The EVIDENCE Trial. Neurology, 59: 1496-1506, 2002.

  7. CLANET M., RADUE E.W., KAPPOS L., HARTUNG H.P., HOHLFELD R., SANDBERG-WOLLHEIM M., KOOIJMANS-COUTINHO M.F., TSAO E.C., SANDROCK A.W., AND THE EUROPEAN IFNß -1a (Avonex) Dose-Comparison Study Investigators. A randomised, double-blind, dose-comparison study of weekly interferon ß-1a in relapsing MS. Neurology, 59:1507-1517.

  8. MEINL E., HOHLFELD R. Immunopathogenesis of multiple sclerosis: MBP and beyond. Clinical and Experimental Immunology, 128: 395-397, 2002. (Editorial Review)

  9. WIENDL H., HOHLFELD R. Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. Biodrugs, 16: 183-2000.

  10. SCOLDING N.J., WILSON H., HOHLFELD R., POLMAN C., LEITE I., GILHUS N. (THE EFNS CEREBRAL VASCULITIS TASK FORCE). The recognition, diagnosis and management of cerebral vascultitis: a European survey. European Journal of Neurology, 9: 343-347, 2002. (EFNS Task Force review)

  11. HOHLFELD R. How promising is hematopoetic stem cell transplantation in multiple sclerosis? Journal of Neurology, 249: 1147-1149, 2002.

  12. HOHLFELD R. Myelin failure in multiple sclerosis: Breaking the spell of Notch. Nature Medicine, 8: 1075-1076, 2002.

  13. WIENDL H, MITSDOERFFER M, HOFMEISTERV, WISCHHUSEN J, WEISS EH, DICHGANS J, LOCHMÜLLER H, HOHLFELD R, MELMS A, WELLER M. The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain, 126: 176-185, 2003.

  14. HOHLFELD R. Hunting (auto)immune T cells in neuroimmunological diseases. Brain, 126: 2-4, 2003 (Editorial)

  15. WIENDL H, MITSDOERFFER M, SCHNEIDER D, MELMS A, LOCHMÜLLER H, HOHLFELD R, WELLER M. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain, 126: 1026-1035, 2003.

  16. HOFBAUER M, WIESENER S, BABBE H, ROERS A, WEKERLE H, DORNMAIR K, HOHLFELD R, GOEBELS N. Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proceedings of the National Academy of Sciences USA, 100: 4090-4095, 2003.

  17. KERSCHENSTEINER M, STADELMANN C, DECHANT G, WEKERLE H, HOHLFELD R. Neurotrophic cross-talk between the nervous and immune systems: Implications for neurological diseases. Annals of Neurology, 53: 292-304, 2003. (Review)

  18. DALAKAS M, HOHLFELD R. Polymyositis and dermatomyositis. Lancet, 362: 971-982, 2003.

  19. WEKERLE H, HOHLFELD R. Molecular mimicry in multiple sclerosis. New England Journal of Medicine, 349: 185-186, 2003.

  20. HOHLFELD R, DALAKAS M. Basic principles of immunotherapy for neurologic diseases. Seminars in Neurology, 23: 121-131, 2003. (Review)

  21. KERSCHENSTEINER M, HOHLFELD R. Neurotrophic factors protect myelin from attack. International MS Journal, 10: 2-4, 2003. (Editorial)

  22. DORNMAIR K, GOEBELS N, WELTZIEN HU, WEKERLE H, HOHLFELD R. T-cell mediated autoimmunity: Novel techniques to characterize autoreactive T-cell receptors. American Journal of Pathology, 163: 1215-1226, 2003.

    23.